Vancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with t

Flu cases have begun to steady but hospital cases still surpassed 3,000 in the week before Christmas, a slight fall on the week before, according to new figures published today. Thanks in part to NHS staff ramping up vaccination efforts with half a million more people protected against flu compared to the same period last year, flu cases have not risen further. Hospitals still remain extremely busy with around 95 per cent of adult beds filled and 94,118 patients in hospital each day. Other winte

JEDDAH, SAUDI ARABIA, December 31, 2025 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Jeddah has manufactured and introduced a post-transplant booster dose for bone marrow transplant patients, an advanced cellular immunotherapy designed to support transplant success and reduce the risk of relapse. The milestone is a first for the Western Region’s healthcare sector, giving patients quicker, safer access to specialized follow-up care while sparing them the

SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its Adalimumab Injection 9MW0113 (Marketed as JUNMAIKANG in China) has been granted marketing authorization by the Indonesian Food and Drug Authority (Badan Pengawas Obat dan Makanan, BPOM). This marks the third overseas marketing approval obtained by Mabwell so far this year. Co-developed by Mabwell and Junshi Biosciences, 9MW0113 has

Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entryNEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, r

Bagsværd, Denmark, 31 December 2025 – Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent. Novo Nordisk is pleased that the Court has upheld the Beijing IP Court ruling recognising the validity of the semaglutide compound patent. “This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” said Mike Doustdar, president and CEO of N

Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited a dramatic shift in metabolic disease investment[1], with late-2025 M&A activity reaching record valuations as major pharmaceutical companies race to secure curative platforms over symptom-management franchises[2]. This pivot toward functional cures rather than chronic insulin dependence is defining

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication, titled “Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma” was published in the Journal of Cancer

MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union Agreement complements KOL collaboration with Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris that accounts for approximately 8% of all CLTI cases in France BERKELEY, Calif, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Prof